When single-cell-level viability was quantified from the multiplexed (i.e., cell count plus viability) screens, it provided information on both the susceptibility and resistance response of cancer cells to druggable target knockdowns such as CYP2A6 and ONECUT2 genes. This evidence concerns the gene CYP2A6 and cancer.